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Abstract: Tibolone is a synthetic molecule used extensively for the management of menopausal 
symptoms, with the proposed additional advantage of enhanced mood and libido. Tibolone, 
after oral administration, is rapidly converted into 3 major metabolites: 3α-hydroxytibolone and 
3β-hydroxytibolone, which have estrogenic effects, and the Δ4-isomer, which has progestogenic 
and androgenic effects. The tissue-selective effects of tibolone are the result of metabolism, of 
enzyme regulation, and of receptor activation which vary in different tissues. Tibolone seems to 
be effective on estrogen-withdrawal symptoms such as hot ﬂ  ushes, sweating, insomnia, headache, 
and vaginal dryness, with results generally comparable to the effects exerted by estrogen-based 
treatments, and the additional property of a progestogenic activity on the endometrium. As 
well as relieving vasomotor symptoms, tibolone has positive effects on sexual well-being and 
mood, and improves dyspareunia and libido. These effects may depend on both estrogenic and 
androgenic actions exerted at the genital level and in the central nervous system, and on a reduc-
tion of sex-hormone-binding globulin and an increase of free testosterone, without affecting 
Δ-5 androgens levels. Based on the evidence available, tibolone is a valuable treatment option 
to relieve menopausal complaints, especially in women suffering persistent fatigue, blunted 
motivation, and loss of sexual desire despite an adequate estrogen replacement.
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Introduction
The climateric period and the postmenopause are characterized by several endocrine, 
neuroendocrine, and metabolic modiﬁ  cations that produce a variety of short-term 
and long-term symptoms. The short-term consequences are represented by vaso-
motor instability (hot ﬂ  ushes and sweats), psychiatric or neurological disturbances 
(depression, anxiety, migraine–headhaches, insomnia), and dyslipidemia. Long-term 
consequences are represented by vaginal dryness dyspareunia, decrease of libido, 
urinary disturbances (stress incontinence, nicturia), osteoporosis, and increased 
risk of cardiovascular and cerebral diseases (Sherwin 1997; Genazzani et al 2005; 
Lauritzen and Studd 2005).
In women, quality of life (QoL) can be seriously affected during the menopausal 
transition. Since physical and mental health, well-being, social role, and physical 
capacity are essential dimensions of QoL, the physiological changes that occur 
around the time of menopause are likely to alter a woman’s perceived QoL (Kuh et al 
1997; Short 2003). A large body of evidence suggests that estrogens, progestins, and 
androgens can induce several effects in different brain areas of the central nervous 
system (CNS) through binding with speciﬁ  c receptors. The actions of sex hormones 
are not limited to the regulation of endocrine functions and mating behaviour: 
experimental and clinical evidence conﬁ  rms an involvement of sex hormones in Neuropsychiatric Disease and Treatment 2006:2(3) 300
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controlling well- being, cognitive functions, and memory 
processes in physiological as well as in pathological condi-
tions (Genazzani et al 1996; McEwen 1999; McEwen and 
Alves 1999).
Changes in female sex steroids and especially changes in 
estrogen concentration are thought to be responsible for the 
occurrence of vasomotor symptoms and other menopause-
related complaints. As a result, hormone replacement therapy 
(HRT) has been suggested to relieve these symptoms and 
therefore affect QoL (Genazzani 2004).
Although estrogen–progestin replacement therapy 
is considered the most effective approach to manage 
menopausal symptoms, several studies have focused on 
androgen replacement therapy, especially for patients 
suffering from sexual disorders, loss of pubic and axil-
lary hair, loss of well-being and energy, mood disorders, 
and metabolic and bone mass effects despite apparently 
adequate estrogen replacement. All these symptoms are 
part of the androgen deﬁ  ciency syndrome (Sherwin 1991; 
Davis and Burger 1996; Davis 1999, 2002b; Davis and 
Tran 2001; Rosen et al 2002). Tibolone (Livial®; Organon, 
Oss, the Netherlands) is a synthetic steroid with estrogenic, 
progestagenic, and androgenic properties. It is structurally 
different from estradiol and selective oestrogen-receptor 
modulators (SERMs) and, unlike the latter compounds, 
its metabolites play a key role in its mechanism of action. 
Tibolone is used extensively in Europe and Asia for the 
management of menopausal symptoms with the proposed 
additional beneﬁ  t of improved mood and libido (Albertazzi 
et al 1998; Davis 2002a; Modelska and Cummings 2002; 
Kenemans and Speroff 2005). The mechanism of action 
of tibolone and its effect on mood, well-being, cognition, 
and sexuality, from basic science to clinical trials, are 
reviewed.
Pharmacology of tibolone
Tibolone has a 3-keto-Δ5-10 steroid structure with 
17α-ethynyl and 7α-methyl groups. It is very rapidly 
metabolized to 3α-hydroxy tibolone and 3β-hydroxy 
tibolone by hepatic and intestinal 3α-hydroxysteroid dehy-
drogenase and 3β-hydroxysteroid dehydrogenase (HSD). 
Both hydroxy-metabolites have a half-life of approximately 
7 hours, but circulatory levels of the 3α-hydroxy metabo-
lite are about 4 times higher than that of the 3β-hydroxy 
metabolite. These two metabolites are responsible for the 
estrogenic activity of tibolone. A third metabolite, the 
Δ4-isomer of tibolone, has progestogenic and androgenic 
properties (Kloosterboer 2004). It is formed directly from 
tibolone by 3-HSD-isomerase, for which the 3α-hydroxy 
metabolite is also a potential substrate. Tibolone is not a 
substrate for 3β-HSD type I or type II, and the conversion 
is therefore most likely due to 3β-HSD activity residing 
in 17β-HSD type II (Suzuki et al 2000). Like the parent 
compound, the Δ4-isomer is rapidly removed from the cir-
culation. This metabolite can also be formed locally from 
tibolone in the endometrium, where it prevents estrogenic 
stimulation (Tang et al 1993).
Tibolone has structural similarities to norethynodrel and 
norethisterone, but these compounds lack the 7α-methyl 
group of tibolone that is a key substituent in determining 
steroid metabolism. The presence of the 7α-methyl group 
means that the Δ4-isomer is not subject to 5α-reduction and 
therefore it retains its progestogenic activity in the endo-
metrium for considerably longer (Zdravkovic et al 2001; 
Timmer and Houwing 2002).
Most metabolites of tibolone (approximately 80%) are in 
the inactive mono-sulfated and di-sulfated forms, from which 
active estrogenic 3-hydroxy metabolites may be continuously 
formed via the sulfatase enzyme, depending on the local 
enzyme activity level. The 3α-hydroxy sulfated tibolone 
is the main sulfated metabolite (de Gooyer et al 2001). In 
transactivation studies, using cells transfected with human 
estrogen receptor and a –reporter construct, the two 3-hydroxy 
metabolites of tibolone appear to be full agonists at the human 
estradiol receptor. Although the 3-hydroxy metabolites are 
weaker agonists than estradiol, a full estrogen response can 
be obtained due to the high circulating levels (de Gooyer 
et al 2003). The 3-hydroxy metabolites of tibolone show 
a selectivity for the classical estrogen receptor α over the 
β isoform. Tibolone itself has been shown to slightly activate 
the estradiol receptor, despite lacking a hydroxyl group and 
an aromatic A-ring (de Gooyer et al 2003). The Δ4-isomer of 
tibolone activates the progesterone and androgen receptors 
but not the estrogen receptor, and has a higher afﬁ  nity for 
progesterone receptor type B than for type A. Tibolone and 
its metabolites have no afﬁ  nity for the glucocorticoid recep-
tor and indeed show no anti-hormonal activity at any steroid 
receptors (Schoonen et al 2000). The androgenic activity of 
the Δ4-isomer may play a role in the liver and brain. In the 
liver, favorable effects are seen on hemostasis, although the 
effects on lipids, particularly the decrease in high-density 
lipoprotein (HDL)-cholesterol, remain controversial. The 
monkey studies of Clarkson’s group indicate, however, that 
the tibolone-induced reduction in HDL-cholesterol does 
not translate into unfavorable effects on the cardiovascular 
system (Register et al 2002). The favorable effects on the Neuropsychiatric Disease and Treatment 2006:2(3) 301
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brain, such as improvements in mood and libido, may be a 
reﬂ  ection of the androgenicity of the Δ4-metabolite.
In contrast to its actions in other tissues such as bone, 
in the breast tibolone inhibits the sulfatase enzyme, and 
the sulfated metabolites in breast tissue are not activated. 
Furthermore, this tissue-speciﬁ  c sulfatase inhibition may 
reduce desulfation of estrone sulfate by breast tissue. 
Tibolone inhibits human breast cell proliferation and 
stimulates apoptosis (Gompel et al 1997). The incidence 
of breast tenderness is low and mammographic density 
does not increase with tibolone, which is unlike classical 
hormone replacement (Hammar et al 1998; Valdivia and 
Ortega 2000).
The conclusion is that tibolone has a selective mode 
of action, and that it belongs to a separate class of drugs. 
Tibolone can be characterized as a selective tissue-
estrogenic-activity regulator (STEAR). In the term STEAR, 
the focus is on the estrogenic activity, which is expressed in 
a tissue-selective manner and in which steroid metabolism 
plays a pivotal role in determining ligand availability for the 
receptor (Reed and Kloosterboer 2004).
Tibolone, mood, and well-being
Menopause-associated symptoms impair QoL for many 
women. More than 75% of postmenopausal women experi-
ence hot ﬂ  ushes and sweating. Other symptoms, such as 
insomnia, headache, or fatigue, as well as changes in mood 
and libido, may result directly from menopause or indi-
rectly, such as effects of hot ﬂ  ushes on sleep disturbances. 
Throughout the climacteric period, the decline in ovarian sex 
steroid production is associated with a change in the turnover 
of various neurotransmitters and neuropeptides, which is 
improved by estrogen administration. Estrogen administra-
tion positively affects not only vasomotor instability, thus 
reducing the number and intensity of hot ﬂ  ushes and sweats, 
but also seems to ameliorate the psychological disturbances 
of menopause, such as depression, and sexual and affective 
behavior disorders (Genazzani 2004).
The effects of estrogen on mood in postmenopausal 
women are mostly related to the direct effect of estrogen on 
neural activity and to the modulation of adrenergic, dopami-
nergic, and serotoninergic tone (McEwen and Alves 1999). 
This estrogen action increases also the action of drugs that act 
on serotonin, such as selective serotonin reuptake inhibitors 
(SSRIs) (Stahl 2001).
No data are available on the direct effect of tibolone on 
central neurotransmitter levels. However, tibolone did not 
enhance the antidepressant effect of the SSRI ﬂ  uoxetine in 
a group of postmenopausal patients with major depressive 
episodes (Berlanga et al 2003).
Estrogens directly modulate endogenous opioid activity 
as well as directly stimulating opioid receptor expres-
sion and by acting on the opiatergic pathway. Circulating 
modiﬁ  cations of β-erythropoietin (Ep) levels may be con-
sidered markers of neuroendocrine function. A decrease in 
plasma β-Ep levels has been detected in postmenopausal 
women after surgical or spontaneous menopause (Aleem 
and McIntosh 1985), and this decrease has been suggested 
to have a role in the mechanisms of hot ﬂ  ushes and sweats 
episodes (Linghtman et al 1981; Genazzani et al 1984). 
The decrease in plasma β-Ep levels has also been related 
to the pathogenesis of mood, behaviour, and nociceptive 
disturbances occurring in this period (Petraglia et al 1993). 
Indeed, a positive role of HRT on vasomotor and subjective 
psychobehavioral symptoms may be mediated by acting on 
the opiatergic pathway (Genazzani et al 1990; Petraglia et al 
1993). In fact, oral estrogen replacement therapy (ERT) after 
spontaneous or surgically induced menopause is followed 
by a signiﬁ  cant increase in circulating β-endorphin levels 
(Genazzani et al 1988; Stomati et al 1997). It has been 
demonstrated that the oral administration of tibolone in 
ovariectomized rats is able to increase the β-endorphin levels 
in pituitary and plasma similarly to the administration of 
estradiol benzoate (Genazzani et al 1987).
The effects of tibolone on β-endorphin and β-lipotropin 
(LPH) have been compared with conjugated equine estro-
gens (CEE) and placebo in symptomatic postmenopausal 
women. After 2 months of treatment both groups of patients 
who underwent steroid supplementation showed circulating 
levels of β-Ep and β-LPH higher than basal levels. Tibolone 
treatment increased β-Ep and β-LPH levels more than con-
jugated estrogens at the 2nd month of therapy. No further 
change was found after 4 months (Genazzani et al 1988) 
(Figure 1). Both treatments alleviated hot ﬂ  ushes and physical 
and psychological symptoms, but the effects of tibolone may 
involve not only estrogenic action but also androgenic effects, 
because testosterone modulates the amount of β-endorphin 
in the anterior pituitary in castrated male rats, and women 
with polycystic ovarian disease, which is characterized by 
hyperandrogenism, have elevated plasma β-endorphin levels 
(Aleem and McIntosh 1984; Forman et al 1985).
While steroid-metabolizing enzymes induce the CNS 
able to modify circulating steroids, the CNS is also able 
to synthesize steroids from cholesterol, at least in part, 
independently of peripheral steroidogenic gland secretion 
(Baulieu 1991), leading to the production of a series of Neuropsychiatric Disease and Treatment 2006:2(3) 302
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potent steroidal compounds. These brain-produced steroids 
have been named ‘‘neurosteroids’’, and have been found to 
exert important regulatory actions on neurons and glial cells 
(Baulieu 1997; Baulieu et al 2001).
Several studies have shown that some psychological func-
tions and symptoms such as depression, anxiety, irritability, 
and affectivity can affect the ﬂ  uctuation of the synthesis and 
the release of the neurosteroids and in particular of allopreg-
nanolone and dehydroepiandrosterone (DHEA) (Majewska 
1992). Allopregnanolone acts as an agonist on γ-aminobutyric 
acidA (GABAA) receptors, modulating stress, mood, and 
behavior with anxiolytic, sedative, and antiepileptic effects 
(Genazzani et al 1995). Ovariectomy signiﬁ  cantly decreases 
allopregnanolone levels both in serum and in the CNS while 
it increases the adrenal content of allopregnanolone. On the 
other hand, when 17β-estradiol is administered to castrated 
female rats allopregnanolone levels increase in the hippocam-
pus, hypothalamus, pituitary, and serum, while they decrease 
in adrenals (Genazzani et al 1995; Stomati et al 2002). 
Tibolone administration in ovariectomized rats induces 
a signiﬁ  cant increase in CNS allopregnanolone content 
particularly in the frontal lobe, parietal lobe, hippocampus, 
and hypothalamus (Figure 2). Similarly, the serum levels of 
allopregnanolone increase while its levels in adrenal glands 
decrease signiﬁ  cantly after treatment (Genazzani et al in 
press). The effects of tibolone on allopregnanolone levels 
have been compared with different hormonal treatments in 
postmenopausal women. After 1 month, all patients who 
underwent tibolone and estrogen-based supplementation 
showed circulating levels of allopregnanolone higher than 
basal levels. After 1 year of treatment, tibolone increased allo-
pregnanolone levels, but to a lesser extent than transdermal 
estradiol, CEE+medroxyprogesterone acetate (MPA), and 
estradiol (E2)+norethisterone acetate (NETA). These results 
let us speculate that mood changes described after HRT as 
well as after tibolone administration might depend also on 
the increased levels of allopregnanolone, a neurosteroid with 
sedative and anxiolytic properties (Pluchino et al 2005).
Several other clinical studies have examined the impact of 
tibolone administration on mood scales and QoL-measuring 
questionnaires. In a placebo-controlled, crossover study 
of 256 postmenopausal women, total weekly mood score 
improved, measured using a 16-item visual analog scale 
(Tax et al 1987). In a randomized, double-blind study Crona 
et al (1988) found that tibolone and E2 valerate reduced 
hot ﬂ  ushes and improved mood to a similar degree (Crona 
et al 1988). In another randomised, double-blind, placebo-
controlled study in healthy postmenopausal women, assessing 
QoL with the Nottingham Health Proﬁ  le, tibolone-treated 
women showed a positive trend compared with placebo, 
especially for sleep and physical mobility. However, the 
sample size of this study was not sufﬁ  cient to show statistical 
signiﬁ  cance, considering the high individual variation in QoL 
measures (Meeuwsen 2002).
Ross et al (2000) investigated the psychological 
effects of tibolone versus CEE 0.625 mg/day with cyclical 
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norgestrel 150 μg using the Women’s Health Questionnaire 
and the Irritability, Depression, and Anxiety Scale. Both 
treatments improved psychological symptoms to a similar 
extent. In conclusion, basic science and clinical studies have 
reported mainly beneﬁ  cial effects of tibolone on mood and 
well-being generally, comparable to those of estrogen-based 
treatments.
Tibolone and cognition
The term cognition encompasses the spectrum of intellectual 
abilities, including attention, learning and memory, language, 
perception, abstract reasoning, and judgment. There is much 
evidence that estrogen may affect cognitive skills. However, 
even if one assumes the validity of positive ﬁ  ndings, it is still 
important to consider whether the estrogen effects might be 
mediated indirectly. Both depression and anxiety can affect 
cognitive performance in older persons, and estrogen may 
mediate mood and reduce stress. It is likely that estrogen does 
inﬂ  uence cognitive skills independently of mood, but this 
caveat should be heeded in interpreting clinical data.
Pan et al compared cognitive function in postmenopausal 
women receiving continuous HRT CEE (0.625 mg/day) 
and MPA (5 mg/day), and women receiving tibolone 
(2.5 mg/day) in a prospective, single-blind, randomized 
study. The Cognitive Abilities Screening Instrument (CASI) 
and Mini-Mental State Examination (MMSE) scores of the 
CEE+MPA group and of the tibolone group after 3 and 
6 months of treatment showed an increasing trend in CASI 
and MMSE levels after treatment, although the increases 
were not statistically signiﬁ  cant. The rate of increase of 
both CASI and MMSE scores in the CEE+MPA group was 
greater than in the tibolone group, though again the differ-
ence was not signiﬁ  cant. The authors conclude that tibolone 
can preserve cognitive function and may be able to prevent 
cognitive decline in postmenopausal women during short-
term treatment (Pan et al 2003). In an open study, Fluck et al 
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investigated the cognitive performance of 25 women who 
had been taking tibolone (2.5 mg/day) for approximately 
10 years. Each woman in this group was pair-matched to 
one in the control group on age, years since menopause, IQ, 
years of secondary education, and occupation. The tibolone 
group did not show the increase in stress, anxiety, and mental 
slowness that the control group showed, after performing 
the Paced Auditory Serial Addition Test (PASAT). These 
effects resulted in an enhanced cortisol response to the stress 
of cognitive testing. It has been demonstrated that young 
women and postmenopausal women taking estrogens show 
a marked increase in anxiety after the PASAT, whereas this 
is not shown by young men. This raises the interesting pos-
sibility that the protective effect of tibolone against stress 
might be due to the activation of the androgen receptors 
by the Δ4-isomer (Fluck et al 2002). In addition, the group 
taking tibolone had signiﬁ  cantly better semantic memory 
(memory for facts), as assessed in a category generation task, 
but they did not differ in tests of episodic memory (memory 
for events). Semantic memory represents our knowledge of 
the world and is an elaborated form of memory that is not 
tied to a speciﬁ  c place or time. The improvement in this 
function that was found in the women treated with tibolone 
could have very real beneﬁ  ts in everyday life. An unexpected 
ﬁ  nding was that the tibolone group performed signiﬁ  cantly 
worse on a sustained attention task and a planning task, 
properties that are associated with frontal lobe function 
(Fluck et al 2002).
Similar results have been reported by another random-
ized study that investigated the effects of tibolone and 
E2+NETA administration on cognitive function in post-
menopausal women. Both groups showed an improvement 
of semantic memory, but only the E2+NETA treatments 
showed an effect on recognition memory (Albertazzi 
et al 2000).
In conclusion, results from these studies suggest that 
tibolone potentially confers beneﬁ  ts on cognitive perfor-
mance. However, several variables can affect cognition in 
postmenopausal women such as the type of HRT, the dura-
tion of treatment, the nature of the cognitive test, and the 
underlying brain structure mediating the particular cognitive 
function. Further long-term and speciﬁ  cally designed studies 
are needed of such effects.
Tibolone and sexuality
Sex hormones play a crucial role in maintaining the 
anatomical and functional integrity of all the structures 
involved in women’s sexual response. While the role of 
estrogen on the activity of neuroendocrine circuitries and 
on the trophism of genital organs has been well established, 
the contribution of androgens to female physical and mental 
well-being is still a matter of debate (Davis and Burger 
1996). A large number of studies suggest that tibolone 
may improve sexual function. This is plausible because 
testosterone (T) has been shown to increase libido and 
frequency of sexual activities, and tibolone has androgenic 
activity. Speciﬁ  cally, as noted earlier, the Δ4-isomer of 
tibolone stimulates the androgen receptor. In addition, tibo-
lone may act indirectly to decrease sex-hormone-binding 
globulin (SHBG) concentrations and thereby increase the 
availability of  T. Postmenopausal women have, on the aver-
age, 30% lower circulating T levels than those measured 
in premenopausal women (Davis and Burger 1996; Davis 
and Tran 2001). Dören and colleagues found that women 
treated with tibolone had higher free T levels and lower 
SHBG levels than women treated with E2+NETA (Dören 
et al 2001). Recent data have demonstrated that circulating 
levels of DHEA decrease progressively and signiﬁ  cantly 
during 12 months of treatment using various estrogen or 
estrogen-progestin molecules, regimens, and routes of 
administration. On the contrary, tibolone does not induce 
any modiﬁ  cation in circulating levels of DHEA. As conse-
quence, unlike estrogen-based therapy, tibolone does not 
affect the androgen milieu in postmenopausal women and 
does not aggravate the physiological androgen deﬁ  ciency 
syndrome (Pluchino et al 2005) (Figure 3).
A recent double-blind, placebo-controlled trial by Laan 
and van Lunsen (2001) showed that treatment with tibolone 
signiﬁ  cantly improved the physiological aspects of sexual 
function in postmenopausal women and subjective measures 
such as sexual desire and arousability. There was no dif-
ference in frequency of sexual intercourse, nonpenetrative 
sexual activity, or initiation and rejection of sexual activity 
between women who were taking tibolone versus those 
receiving placebo. However, the small sample size in the 
subgroups may have diminished the power to detect statisti-
cal differences between these variables. In another trial, an 
improvement in sexual function with regard to frequency, 
satisfaction, and enjoyment compared with baseline was 
recognized (Nathorst-Böös and Hammar 1997). Castelo-
Branco et al, in a prospective study, enrolled 120 surgical 
postmenopausal women who received oral E2 valerate 
(4 mg/day) with dihydroandrosterone enanthate (monthly, 
intramuscularly), transdermal 17β-estradiol (50 μg/day), 
tibolone (2.5 mg/day), or placebo for 12 months. Sexuality 
improved signiﬁ  cantly with all treatments, but the combined Neuropsychiatric Disease and Treatment 2006:2(3) 305
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regimen of androgens and ERT increased sexual activity in 
postmenopausal women equal to that of tibolone and to a 
greater extent than ERT alone (Castelo-Branco et al 2000). 
These data, together with the recent observation that tibolone 
signiﬁ  cantly increases vaginal pulse amplitude at baseline 
and following erotic stimulation compared with placebo 
(Laan and van Lunsen 2001), further supports the notion 
that such a tissue-speciﬁ  c compound is a good therapeutic 
option to relieve low libido, arousability, and lubrication at 
menopause because of both its estrogenic and androgenic 
properties.
Conclusion
Data originating from basic science and from clinical trials 
highlight that tibolone exerts encouraging effects on climac-
teric symptoms. These effects have been attributed to its 
unique molecular proﬁ  le and to the tissue-related metabolism 
into estrogenic, progestogenic, and androgenic metabolities 
(Figure 4). In particular, tibolone seems to be effective on 
estrogen-withdrawal symptoms such as hot ﬂ  ushes, sweating, 
and vaginal dryness, with results generally comparable to the 
effects exerted by estrogen-based treatments. In addition, 
during postmenopause women commonly report symptoms 
related to both estrogen and androgen deprivations such 
as low libido, persistent fatigue, blunted motivation, and a 
general reduced sense of well-being. Evidence implies that 
tibolone is able to increase arousal and libido in postmeno-
pausal women to a greater extent than estrogen therapy 
alone. These effects may be dependent on both estrogenic 
and androgenic actions exerted at the genital level and in the 
CNS, and to a reduction of SHBG and an increase of free T, 
without affecting Δ-5 androgens levels. Data on the effects of 
tibolone on cognitive function are not sufﬁ  cient to establish 
if estrogen-based therapies are more effective than tibolone 
in improving cognitive processes in postmenopausal women. 
Further long-term and speciﬁ  cally designed studies are 
needed on such effects.
In conclusion, the pharmacological profile and the 
clinical effects of tibolone make this synthetic steroid an 
additional option for clinicians in selecting the most appro-
priate treatment to counteract individually the physical and 
psychological symptoms of each postmenopausal woman.
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